Nykode Therapeutics

Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company dedicated to the discovery of novel immunotherapies. Nykode’s vision is to become a leading immunotherapy company, developing therapeutics across a range of areas with high unmet medical need, such as cancers and autoimmune diseases.

Equities

Equities by Sector

Sectors

Thematics

Latest

Molten Ventures is looking to invest in tech companies that see new ways for the world to work

Edison explains: AI’s bubble watch – central banks flag dot-com-level valuations

Edison explains: Seven strategic powers – understanding sustainable competitive advantage

Audiovisual

Latest

Mendus – executive interview

Edison Explains: Seven strategic powers – understanding sustainable competitive advantage

Custodian Property Income REIT – executive interview

About Edison

About Edison

Careers

Nykode Therapeutics (NYKD)

Latest Insights

Nykode Therapeutics — Repositioned to streamline clinical progress

Sector

Equity Analyst

Research

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time